Floatz logo

flt3 ligand

Primary Peritoneal Cancer

Celldex TherapeuticsPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

55 Active assets in the Primary Peritoneal Cancer cohort.

Asset / SponsorPhaseRating
Mirvetuximab Soravtansine
AbbVie
Phase 3BB
Irinotecan
Tianjin Medical University Cancer Institute and Hospital
Phase 3BB
(+)-VINCRISTINE
AbbVie
Phase 3BB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BB
Inno-206
Regeneron Pharmaceuticals
Phase 3BB

View all 50 →

Same molecule, other indications

flt3 ligand is also rated in:

Recurrent Renal Cell CancerDormant
B
Indicative ·
57 / 100
View asset →
Chronic Lymphocytic Leukemia (CLL)Dormant
CCC
Indicative ·
55 / 100
View asset →
Indolent B-cell LymphomasDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →